The Role of ElastPQ in Assessing Liver Stiffness for Non-Alcoholic Fatty Liver Disease in Patients Treated with Atypical Antipsychotic Drugs

References

• De Oliveira IR, Juruena MF. Treatment of psychosis: 30 years of progress. J Clin Pharm Ther. 2006;31:523–534. doi:10.1111/j.1365-2710.2006.00784.x
   PubMed Web of Science ®Google Scholar
• Ahmer S, Khan RA, Iqbal SP. Association between antipsychotics and weight gain among psychiatric outpatients in Pakistan: a retrospective cohort study. Ann Gen Psychiatry. 2008;7(1):12. doi:10.1186/1744-859X-7-12
   PubMedGoogle Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765–1773. doi:10.1001/jama.2009.1549
   PubMed Web of Science ®Google Scholar
• Diehl AM, Day C, Longo DL. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377(21):2063–2072. doi:10.1056/NEJMra1503519
   PubMed Web of Science ®Google Scholar
• Li Z, Xue J, Chen P, Chen L, Yan S, Liu L. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol. 2014;29(1):42–51. doi:10.1111/jgh.12428
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation. 2019;103:22–27. doi:10.1097/TP.0000000000002484
   PubMed Web of Science ®Google Scholar
• Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28(Suppl 4):64–70. doi:10.1111/jgh.12271
   PubMed Web of Science ®Google Scholar
• Huang X, Liu X, Yu Y. Depression and chronic liver diseases: are there shared underlying mechanisms? Front Mol Neurosci. 2017;10:134. doi:10.3389/fnmol.2017.00134
   PubMed Web of Science ®Google Scholar
• Hsu JH, Chien IC, Lin CH, Chou YJ, Chou P. Increased risk of chronic liver disease in patients with schizophrenia: a population-based cohort study. Psychosomatics. 2014;55:163–171. doi:10.1016/j.psym.2013.06.001
   PubMed Web of Science ®Google Scholar
• Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–690. doi:10.1038/nrgastro.2013.171
   PubMed Web of Science ®Google Scholar
• Ferraioli G, Berzigotti A, Barr RG, et al. Quantification of liver fat content with ultrasound: a WFUMB position paper. Ultrasound Med Biol. 2021;47(10):2803–2820. doi:10.1016/j.ultrasmedbio.2021.06.002
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi:10.1002/hep.20701
   PubMed Web of Science ®Google Scholar
• Berzigotti A. Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: controlled attenuation parameter for steatosis. J Hepatol. 2014;60(5):910–912. doi:10.1016/j.jhep.2014.01.017
   PubMed Web of Science ®Google Scholar
• Gunn NT, Shiffman ML. The use of liver biopsy in nonalcoholic fatty liver disease: when to biopsy and in whom. Clin Liver Dis. 2018;22(1):109–119. doi:10.1016/j.cld.2017.08.006
   PubMed Web of Science ®Google Scholar
• Dietrich CF, Shi L, Lowe A, et al. Conventional ultrasound for diagnosis of hepatic steatosis is better than believed. Z Gastroenterol. 2022;60(08):1235–1248. doi:10.1055/a-1491-1771
   PubMedGoogle Scholar
• Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep. 2013;1:19–26. doi:10.1093/gastro/got007
   Google Scholar
• Jiang W, Huang S, Teng H, et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open. 2018;8(8):e021787. doi:10.1136/bmjopen-2018-021787
   PubMed Web of Science ®Google Scholar
• Argalia G, Tarantino G, Ventura C, et al. Shear wave elastography and transient elastography in HCV patients after direct-acting antivirals. Radiol Med. 2021;126(6):894–899. doi:10.1007/s11547-020-01326-4
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology. 2012;55(6):2005–2023. doi:10.1002/hep.25762
   PubMed Web of Science ®Google Scholar
• Leong WL, Lai LL, Nik Mustapha NR, et al. Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2020;35(1):135–141. doi:10.1111/jgh.14782
   PubMed Web of Science ®Google Scholar
• Conti F, Serra C, Vukotic R, et al. Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C. Liver Int. 2017;37(2):187–195. doi:10.1111/liv.13197
   PubMed Web of Science ®Google Scholar
• Ferraioli G, Tinelli C, Lissandrin R, et al. Point shear wave elastography method for assessing liver stiffness. World J Gastroenterol. 2014;20:4787–4796. doi:10.3748/wjg.v20.i16.4787
   PubMed Web of Science ®Google Scholar
• Ma JJ, Ding H, Mao F, Sun HC, Xu C, Wang WP. Assessment of liver fibrosis with elastography point quantification technique in chronic hepatitis B virus patients: a comparison with liver pathological results. J Gastroenterol Hepatol. 2014;29:814–819. doi:10.1111/jgh.12479
   PubMed Web of Science ®Google Scholar
• Hasin D, Hatzenbuehler ML, Keyes K, Ogburn E. Substance use disorders: Diagnostic and Statistical Manual of mental disorders, fourth edition (DSM-IV) and International Classification of Diseases, tenth edition (ICD-10). Addiction. 2006;101(Suppl 1):59–75. doi:10.1111/j.1360-0443.2006.01584.x
   PubMedGoogle Scholar
• Kundakci T, Sar V, Kiziltan E, Yargic IL, Tutkun H. Reliability and validity of the Turkish version of the Structured Clinical Interview for DSM-IV dissociative disorders (SCID-D): a preliminary study. J Trauma Dissociation. 2014;15:24–34. doi:10.1080/15299732.2013.821434
   PubMed Web of Science ®Google Scholar
• Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663–667. doi:10.4088/JCP.v64n0607
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007;11:37–54, viii. doi:10.1016/j.cld.2007.02.014
   PubMedGoogle Scholar
• Majumdar S, Thakur MB, Ran A. Comparative evaluation of serum copeptin in obesity with non alcoholic fatty liver disease. J Assoc Physicians India. 2023;71:1.
   PubMedGoogle Scholar
• Liang W, Menke AL, Driessen A, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One. 2014;9:e115922. doi:10.1371/journal.pone.0115922
   PubMed Web of Science ®Google Scholar
• Gangopadhyay A, Ibrahim R, Theberge K, May M, Houseknecht KL. Non-alcoholic fatty liver disease (NAFLD) and mental illness: mechanisms linking mood, metabolism and medicines. Front Neurosci. 2022;16:1042442. doi:10.3389/fnins.2022.1042442
   PubMed Web of Science ®Google Scholar
• Beauchemin M, Geguchadze R, Guntur AR, et al. Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: risperidone alters the cardiac proteomic signature in mice. Pharmacol Res. 2020;152:104589. doi:10.1016/j.phrs.2019.104589
   PubMed Web of Science ®Google Scholar
• Bicker J, Alves G, Falcao A, Fortuna A. Timing in drug absorption and disposition: the past, present, and future of chronopharmacokinetics. Br J Pharmacol. 2020;177(10):2215–2239. doi:10.1111/bph.15017
   PubMed Web of Science ®Google Scholar
• Kunst RF, Langlais AL, Barlow D, Houseknecht KL, Motyl KJ. Housing temperature influences atypical antipsychotic drug-induced bone loss in female C57BL / 6J mice. JBMR Plus. 2021;5(10):e10541. doi:10.1002/jbm4.10541
   PubMedGoogle Scholar
• Carnagarin R, Tan K, Adams L, et al. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-a condition associated with heightened sympathetic activation. Int J Mol Sci. 2021;22. doi:10.3390/ijms23010022
   PubMed Web of Science ®Google Scholar
• Ferraioli G, De Silvestri A, Reiberger T, et al. Adherence to quality criteria improves concordance between transient elastography and ElastPQ for liver stiffness assessment-A multicenter retrospective study. Dig Liver Dis. 2018;50(10):1056–1061. doi:10.1016/j.dld.2018.03.033
   PubMedGoogle Scholar
• Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175–1183. doi:10.1001/jama.2020.2298
   PubMed Web of Science ®Google Scholar
• Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–1730. doi:10.1053/j.gastro.2019.01.042
   PubMed Web of Science ®Google Scholar
• Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–1030. doi:10.1016/j.jhep.2016.12.022
   PubMed Web of Science ®Google Scholar
• Hong YM, Yoon KT, Cho M, et al. Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant. Eur J Gastroenterol Hepatol. 2017;29(7):805–810. doi:10.1097/MEG.0000000000000876
   PubMed Web of Science ®Google Scholar
• de Ledinghen V, Hiriart JB, Vergniol J, Merrouche W, Bedossa P, Paradis V. Controlled Attenuation Parameter (CAP) with the XL probe of the fibroscan((R)): a comparative study with the M probe and liver biopsy. Dig Dis Sci. 2017;62:2569–2577. doi:10.1007/s10620-017-4638-3
   PubMed Web of Science ®Google Scholar
• Lee DH, Cho EJ, Bae JS, et al. Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021;19(4):797–805 e797. doi:10.1016/j.cgh.2020.05.034
   PubMed Web of Science ®Google Scholar
• Ling W, Lu Q, Quan J, Ma L, Luo Y. Assessment of impact factors on shear wave based liver stiffness measurement. Eur J Radiol. 2013;82(2):335–341. doi:10.1016/j.ejrad.2012.10.004
   PubMed Web of Science ®Google Scholar
• Sporea I, Bota S, Gradinaru-Tascau O, Sirli R, Popescu A. Comparative study between two point shear wave elastographic techniques: Acoustic Radiation Force Impulse (ARFI) elastography and ElastPQ. Med Ultrason. 2014;16:309–314. doi:10.11152/mu.201.3.2066.164.isp1
   PubMed Web of Science ®Google Scholar
• Lee JE, Shin KS, Cho JS, et al. Non-invasive assessment of liver fibrosis with ElastPQ: comparison with transient elastography and serologic fibrosis marker tests, and correlation with liver pathology results. Ultrasound Med Biol. 2017;43:2515–2521. doi:10.1016/j.ultrasmedbio.2017.07.008
   PubMed Web of Science ®Google Scholar
• da Silva LCM, de Oliveira JT, Tochetto S, de Oliveira C, Sigrist R, Chammas MC. Ultrasound elastography in patients with fatty liver disease. Radiol Bras. 2020;53:47–55. doi:10.1590/0100-3984.2019.0028
   PubMedGoogle Scholar
• Sirli R, Sporea I, Bota S, Jurchis A. Factors influencing reliability of liver stiffness measurements using transient elastography (M-probe)-monocentric experience. Eur J Radiol. 2013;82:e313–e316. doi:10.1016/j.ejrad.2013.03.002
   PubMed Web of Science ®Google Scholar
• Julian MT, Ballesta S, Pera G, et al. Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: a population-based study. Front Endocrinol. 2022;13:1051958. doi:10.3389/fendo.2022.1051958
   PubMed Web of Science ®Google Scholar
• Li XD, Qiu BH, Su FC, Sun SX. Gender impacts on the correlations between nonalcoholic fatty liver disease and hypertension in a Chinese population aged 45–60 y. Clin Exp Hypertens. 2016;38:639–643. doi:10.1080/10641963.2016.1182181
   PubMed Web of Science ®Google Scholar
• Zhao Y, Qiu C, Dong Y, et al. Technical acoustic measurements combined with clinical parameters for the differential diagnosis of nonalcoholic steatohepatitis. Diagnostics. 2023;13(9):1547. doi:10.3390/diagnostics13091547
   Web of Science ®Google Scholar
• Kong L, Yang Y, Li H, Shan Y, Wang X, Shan X. Prevalence of nonalcoholic fatty liver disease and the related risk factors among healthy adults: a cross-sectional study in Chongqing, China. Front Public Health. 2023;11:1127489. doi:10.3389/fpubh.2023.1127489
   PubMed Web of Science ®Google Scholar
• Platanic Arizanovic L, Nikolic-Kokic A, Brkljacic J, et al. Effects of several atypical antipsychotics closapine, sertindole or ziprasidone on hepatic antioxidant enzymes: possible role in drug-induced liver dysfunction. J Toxicol Environ Health A. 2021;84(4):173–182. doi:10.1080/15287394.2020.1844827
   PubMed Web of Science ®Google Scholar
• Bou Khalil R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Clin Neuropharmacol. 2012;35:141–147. doi:10.1097/WNF.0b013e31824d5288
   PubMed Web of Science ®Google Scholar
• Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med. 2006;21:1133–1137. doi:10.1111/j.1525-1497.2006.00563.x
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010:CD006654. doi:10.1002/14651858.CD006654.pub2
   PubMed Web of Science ®Google Scholar